Core Viewpoint - Julie & Holleman LLP is investigating the proposed acquisition of WideOpenWest, Inc. by Crestview Partners and DigitalBridge Investments, citing conflicts of interest and a belief that the acquisition price of $5.20 per share is undervalued [1][4]. Company Overview - WideOpenWest, Inc. (WOW!) is a leading broadband provider in the U.S., operating in 20 markets across the Midwest and Southeast [2]. - Wall Street analysts have set an average one-year stock price target of $5.65 per share for WOW!, with a high target of $6.50 per share [2]. Acquisition Details - On August 11, 2025, WOW! announced an agreement to be taken private at a price of $5.20 per share, with Crestview Partners, which owns 37% of WOW!'s stock, partnering with DigitalBridge to acquire the remaining shares [3]. Legal Concerns - Julie & Holleman LLP is pursuing potential legal claims regarding the fairness of the acquisition deal, highlighting concerns over conflicts of interest as key insiders remain with the company while public shareholders are offered a price below the company's true value [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Venture Global, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors related to the company's initial public offering [1][2] Group 1: Allegations Against Venture Global - The complaint alleges that Venture Global made false and/or misleading statements regarding its ability to deliver liquefied natural gas (LNG) and the development of its five liquefaction and export projects, which depended on customer contracts [2] - It is claimed that Venture Global is facing legal challenges from major clients like BP and Shell due to delays in supply contracts, impacting its business operations [2] - The allegations suggest that Venture Global's business and financial prospects were overstated, potentially misleading investors [2] Group 2: Legal Representation and Contact Information - Bragar Eagel & Squire, P.C. represents individual and institutional investors in complex litigation, including securities and derivative cases [4] - Long-term stockholders of Venture Global are encouraged to contact the firm for more information regarding the claims and their rights [3][6]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Geron Corporation due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1][2] Summary by Relevant Sections Class Action Complaint - The complaint was filed on March 14, 2025, covering a Class Period from February 28, 2024, to February 25, 2025 [1] - Allegations include that Geron's management provided misleading information regarding the launch and growth potential of Rytelo (imetelstat) [2] - The complaint claims that the management expressed confidence in addressing the unmet need for the drug while downplaying risks related to monitoring requirements and competition [2] Investigation Details - The investigation focuses on whether Geron's board of directors has breached their fiduciary duties to the company [1] - Long-term stockholders are encouraged to reach out for more information regarding their rights and the ongoing investigation [3] Law Firm Background - Bragar Eagel & Squire, P.C. is a recognized law firm that represents investors in various complex litigations [4]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Edwards Lifesciences Corporation due to a class action complaint related to the company's fiduciary duties and misleading revenue expectations for its TAVR platform [1][2]. Group 1: Legal Investigation - The investigation is focused on long-term stockholders of Edwards who held shares between February 6, 2024, and July 24, 2024, following a class action complaint filed on December 13, 2024 [1]. - The law firm is encouraging affected investors to discuss their legal rights and options [1][5]. Group 2: Financial Performance and Market Reaction - On July 24, 2024, Edwards reported disappointing financial results for Q2 2024, significantly lowering its revenue guidance for the TAVR platform for the full fiscal year [3]. - The company attributed the decline in TAVR performance to increased pressure on hospital workflows from the growth of other structural heart therapies, including its own TMTT [3]. - Following the announcement, Edwards' stock price plummeted from $86.95 to $59.70 per share, marking a decline of approximately 31.34% in one day [4]. Group 3: Company Strategy - During the second quarter, Edwards announced three acquisitions aimed at enhancing treatments alternative to TAVR, indicating a recognition of the potential slowdown in TAVR growth [3].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Cummins Inc. due to a class action lawsuit alleging breaches of fiduciary duties by the company's board of directors during the specified class period [1][2]. Group 1: Legal Investigation - The investigation is focused on whether Cummins' board of directors has breached their fiduciary duties to the company [1]. - A class action complaint was filed against Cummins on March 15, 2024, covering a class period from April 30, 2019, to December 21, 2023 [1]. Group 2: Allegations in the Lawsuit - The lawsuit claims that Cummins made materially false and misleading statements regarding its compliance with environmental regulations [2]. - It is alleged that Cummins continued to produce engines with unlawful emission defeating devices from 2019 to 2023, contradicting their assurances made post-April 2019 [2]. - The company is accused of understating its legal and regulatory risks while overstating its commitment to environmental protection [2].

Core Viewpoint - Julie & Holleman LLP is investigating the proposed acquisition of WideOpenWest, Inc. by Crestview Partners and DigitalBridge Investments, citing conflicts of interest and a belief that the acquisition price of $5.20 per share is undervalued [1][4]. Company Overview - WideOpenWest, Inc. (WOW!) is a leading broadband provider in the U.S., operating in 20 markets across the Midwest and Southeast [2]. - Wall Street analysts have set an average one-year stock price target of $5.65 per share for WOW!, with a high target of $6.50 per share [2]. Acquisition Details - On August 11, 2025, WOW! announced an agreement to be taken private at a price of $5.20 per share, with Crestview Partners, which owns 37% of WOW!'s stock, partnering with DigitalBridge to acquire the remaining shares [3]. Legal Concerns - Julie & Holleman LLP is pursuing potential legal claims regarding the fairness of the acquisition deal, highlighting concerns over conflicts of interest as key insiders will remain with the company while public shareholders are being cashed out at a price below the company's true value [4].

Core Viewpoint - Johnson Fistel, PLLP has initiated an investigation into MeridianLink, Inc. regarding potential breaches of fiduciary duties by its board members in relation to the proposed sale to Centerbridge Partners, which may undervalue the company’s shares [1][6]. Company Overview - MeridianLink has entered into a definitive merger agreement with Centerbridge Partners, where shareholders will receive $20.00 in cash per share [6]. - The proposed merger price is significantly lower than MeridianLink's 52-week high of $25.33 per share, despite positive projections for the company's sales and revenue growth from Wall Street analysts [6]. Legal Context - The investigation by Johnson Fistel is aimed at assessing whether the board's actions in the sale process are in the best interest of shareholders [1]. - Shareholders who believe the deal undervalues their investment are encouraged to participate in the investigation [3]. Firm Background - Johnson Fistel, PLLP is recognized as a leading shareholder rights law firm with a strong track record in securities class action lawsuits, having recovered approximately $90.725 million for clients [4].

Core Viewpoint - Johnson Fistel, PLLP has initiated an investigation into potential breaches of fiduciary duties by the board members of STAAR Surgical Company regarding the proposed sale to Alcon, which may undervalue the company’s shares [1][2]. Company Overview - STAAR Surgical has entered into a definitive merger agreement with Alcon, where shareholders will receive $28.00 in cash per share [5]. - The merger consideration is significantly lower than STAAR Surgical's 52-week high of $41.00 per share, despite positive projections for the company's sales and revenue growth from Wall Street analysts [5]. Legal Context - Johnson Fistel, PLLP is a recognized shareholder rights law firm that represents both individual and institutional investors in derivative and class action lawsuits [2][3]. - The firm has a history of recovering substantial amounts for clients, having secured approximately $90.7 million in previous cases [3].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Humana Inc. due to a class action lawsuit alleging breaches of fiduciary duties by the board of directors during the specified class period [2][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit against Humana alleges that the company made false or misleading statements regarding its adjusted earnings-per-share, particularly downplaying the impact of increased medical costs from pent-up demand for healthcare services [4]. - On June 13, 2023, UnitedHealth Group Inc. reported higher outpatient care activity, which led to a significant drop of over 11% in Humana's stock price [5]. - Following a report on June 16, 2023, indicating higher than anticipated non-inpatient utilization trends, Humana's stock price fell again, reflecting investor concerns [6]. - On January 18, 2024, Humana disclosed an increase in its benefits expense ratio to approximately 91.4% for Q4 2023, resulting in a nearly 8% decline in stock price [7]. - The announcement of a loss of $4.42 per share for Q4 2023 on January 25, 2024, due to higher inpatient utilization and expected persistent medical costs, caused Humana's stock to drop nearly 12% [8]. Group 2: Company Overview - Humana is a health insurance company that provides medical benefit plans to its members [3].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Micron Technology, Inc. due to a class action complaint alleging that the company's board may have breached their fiduciary duties to shareholders [1][2]. Group 1: Allegations Against Micron - The class action complaint claims that Micron made materially false and misleading statements regarding its business operations and prospects during the class period from September 28, 2023, to December 18, 2024 [2]. - Specific allegations include that demand for Micron's NAND products in consumer markets significantly deteriorated, which was not disclosed, leading to overstated recovery claims regarding product demand [2]. Group 2: Legal Representation and Contact Information - Long-term stockholders of Micron who have suffered losses are encouraged to contact Bragar Eagel & Squire for discussions about their legal rights and potential claims [1][3]. - The law firm offers no-cost consultations for individuals seeking information about the claims or their rights related to the situation [3].